Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Siplizumab bei T1DM (DESIGNATE)

Eine T-Zell-Phänotyp-Signatur-gesteuerte Dosisfindungsstudie mit Siplizumab bei Typ-1-Diabetes mellitus (ITN095AI)

This is a multicenter, Phase Ib, open-label, siplizumab dose-finding study in individuals aged 8-45 years with a Type 1 diabetes mellitus (T1DM) diagnosis. within 18 months of V0. Participants will be randomized 1:1:1:1 to one of four possible siplizumab dosing arms. All dosing arms will receive weekly siplizumab doses for a total of 12 weeks. After the completion of treatment, participants will undergo follow-up visits at weeks 12, 24, 36 and 52 which include longitudinal MMTTs. If indicated, participants will enter into long-term safety monitoring for up to an additional 48 weeks. Blood samples for mechanistic analyses will be obtained during the treatment phase and thereafter. Adults aged 18- 45 will be enrolled initially at the study sites.

The primary objective is to identify a safe, metabolically favorable, dosing regimen for siplizumab in patients with type 1 diabetes that induces changes in T cell phenotypes observed with alefacept therapy in new-onset T1DM.

The secondary objectives are to:

  1. Assess the safety profile of siplizumab in recently diagnosed T1DM.
  2. Assess the effects of siplizumab on residual beta cell function in recently diagnosed T1DM participants.

Studienübersicht

Status

Beendet

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Tatsächlich)

8

Phase

  • Phase 2
  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

    • Colorado
      • Aurora, Colorado, Vereinigte Staaten, 80045
        • University of Colorado School of Medicine: Barbara Davis Center for Diabetes
    • Iowa
      • Iowa City, Iowa, Vereinigte Staaten, 52242
        • University of Iowa Children's Hospital: Department of Pediatrics, Pediatric Endocrinology and Diabetes
    • New York
      • New York, New York, Vereinigte Staaten, 10032
        • Columbia University Medical Center: Naomi Berrie Diabetes Center
    • Texas
      • Dallas, Texas, Vereinigte Staaten, 75390
        • University of Texas Southwestern Medical Center: Department of Internal Medicine, Division of Endocrinology
    • Washington
      • Seattle, Washington, Vereinigte Staaten, 98101
        • Benaroya Research Institute at Virginia Mason: Diabetes Research Program

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

8 Jahre bis 45 Jahre (Kind, Erwachsene)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  1. Ability to provide informed consent (parental permission and informed assent of minor, if applicable).

  2. Male or female between 8 to 45 years of age.

  3. Diagnosis of T1DM within 18 months (550 days) of enrollment (V0).

  4. Positive for at least one diabetes-related autoantibody, including:

    1. Glutamate decarboxylase (GAD-65),
    2. Insulin, if obtained within 10 days of the onset of exogenous insulin therapy,
    3. Insulinoma antigen-2 (IA-2), or
    4. Zinc transporter-8 (ZnT8).
  5. Peak stimulated C-peptide level > 0.15 nmol/L following a MMTT conducted ≥ 21 days from diagnosis and within 37 days of enrollment (V0).

  6. Completion of a SARS-CoV-2 vaccination, according to current CDC recommendations and FDA approval(s) or emergency use authorization(s). If the participant requires administration of vaccine(s) to meet eligibility requirements, they must complete the vaccination series at least 2 weeks prior to enrollment (V0).

Exclusion Criteria:

  1. 1. Use of investigational drugs within 24 weeks of participation with the exception of any vaccine for the prevention of SARS-CoV-2 infection and emergency use authorization medications for treating SARS-CoV-2.

  2. Severe reaction or anaphylaxis to humanized monoclonal antibodies.

  3. Inability to complete a mixed meal tolerance test:

    1. History of significant allergy (e.g., anaphylaxis) to milk or soy proteins.
    2. Inability to disable hybrid closed loop system.
  4. History of recent (within 180 days of V0) or ongoing uncontrolled bacterial, viral, fungal or other opportunistic infections, including:

    1. Human immunodeficiency virus (HIV),
    2. Current or prior infection with hepatitis B (HBV), as indicated by positive HBsAg or positive HBcAb,
    3. Current or prior hepatitis C (HCV), unless treated with anti-viral therapy with achievement of a sustained virologic response (undetectable viral load 12 weeks after cessation of therapy),
    4. Positive QuantiFERON-TB Gold or QuantiFERON-TB Gold Plus tests. PPD or T-SPOT®.TB may be substituted for the QuantiFERON-TB Gold or QuantiFERON-TB Gold Plus tests,
    5. Active infection with EBV as detected by PCR or serology at the screening visit (V-1),
    6. Active infection with cytomegalovirus (CMV) as detected by PCR or serology at the screening visit (V-1),
  5. Positive molecular testing of SARS-CoV-2 within 30 days of V-1.

  6. Any of the following laboratory abnormalities confirmed by repeat tests at least 1 week apart:

    1. White blood count (WBC) < 3 x 103/μL;,
    2. CD 3+ CD4+, T cell count below the lower limit of normal,
    3. Platelet count < 150,000 /μL,
    4. Hemoglobin < 10 g/dL,
    5. ALT ≥ 2x upper limit of normal (ULN) or
    6. AST ≥ 2x ULN
    7. Serum creatinine >1.5x ULN in adults or >ULN in pediatrics.
    8. Absolute lymphocyte count (ALC) below the LLN.
  7. Prior or current treatment that is known to alter the natural history of T1DM or immunologic status, including high dose inhaled, extensive topical or systemic glucocorticoids.

  8. Current or prior (within last 14 days of the V-1 MMTT) use of any medication known to influence glucose tolerance (e.g., atypical antipsychotics, diphenylhydantoin, thiazide, or other potassium-depleting diuretics, β-adrenergic blockers, niacin).

  9. Current or prior (within the last 30 days of the V-1 MMTT) use of non-insulin medications to treat insulin resistance or elevated glucose levels.

  10. Previous or current diagnosis of malignancy.

  11. History of bone marrow transplantation, solid organ transplantation, or primary immunodeficiencies.

  12. History or diagnoses of other autoimmune diseases with the exception of stable thyroid or celiac disease.

  13. History of significant cardiovascular disease.

  14. Vaccination with a live attenuated vaccine (e.g., varicella, measles, mumps, rubella, cold-attenuated intranasal influenza vaccine, bacillus Calmette- Guérin, and smallpox) within 30 days of V0.

  15. Women of child-bearing potential who are unwilling to use a medically acceptable form of contraception from 14 days prior to V0 until study Week 52.

  16. Women who are pregnant, lactating, or planning on pregnancy during the study.

  17. Current, diagnosed mental illness (e.g., severe depression), current diagnosed or self-reported drug, or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements.

  18. Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: Adults with T1D 0.08 mg/kg SQ dose

Cohort 1 Group1: 0.08 mg/kg SQ dose for a total of 12 weeks

Weekly siplizumab doses for a total of 12 weeks

Andere Namen:
  • TCD601
Experimental: Adults with T1D 0.12 mg/kg SQ dose

Cohort 1 Group 2: 0.12 mg/kg SQ dose for a total of 12 weeks

Weekly siplizumab doses for a total of 12 weeks

Andere Namen:
  • TCD601
Experimental: Adults with T1D 0.18 mg/kg SQ dose

Cohort 1 Group 3:0.18 mg/kg SQ dose for a total of 12 weeks

Weekly siplizumab doses for a total of 12 weeks

Andere Namen:
  • TCD601
Experimental: Adults with T1D 0.22 mg/kg SQ dose

Cohort 1 Group 4: 0.22 mg/kg SQ dose for a total of 12 weeks

Weekly siplizumab doses for a total of 12 weeks

Andere Namen:
  • TCD601
Experimental: Children with T1D 0.08 mg/kg SQ dose

Cohort 2 Group 1:0.08 mg/kg SQ dose for a total of 12 weeks

Weekly siplizumab doses for a total of 12 weeks

Andere Namen:
  • TCD601
Experimental: Children with T1D 0.12 mg/kg SQ dose

Cohort 2 Group 2:0.12 mg/kg SQ dose for a total of 12 weeks

Weekly siplizumab doses for a total of 12 weeks

Andere Namen:
  • TCD601
Experimental: Children with T1D 0.18 mg/kg SQ dose

Cohort 2 Group 3: 0.18 mg/kg SQ dose for a total of 12 weeks

Weekly siplizumab doses for a total of 12 weeks

Andere Namen:
  • TCD601
Experimental: Children with T1D 0.22 mg/kg SQ dose

Cohort 2 Group 4: 0.22 mg/kg SQ dose for a total of 12 weeks

Weekly siplizumab doses for a total of 12 weeks

Andere Namen:
  • TCD601

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Number of Participants With a T Cell Phenotype Signature Response
Zeitfenster: Week 0 to Week 12

A participant is defined as achieving a T Cell phenotype signature response if the participant experiences both a 75% increase or greater from baseline in the CD4 Treg/Tem ratio in blood and a 20% increase or greater from baseline in PD1+TIGIT+ frequency within circulating CD4 Tem. The two criteria will be evaluated at weeks 2, 4, 8, and 12. Both criteria do not need to be achieved at the same time point.

Week 0 to Week 12

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Frequency of Adverse Events (AEs) in All Siplizumab Dosing Arms
Zeitfenster: From week 0 to week 100

AE will include any untoward medical occurrence associated with siplizumab administration or any study-mandated procedure. A treatment-emergent adverse event (TEAE) is defined as in increase in grade from baseline or from the last post-baseline value that doesn't meet grading criteria.

From week 0 to week 100
Mixed Meal Tolerance Test (MMTT)-Stimulated Mean 2-hour C-peptide AUC
Zeitfenster: At Weeks 12, 24, 36, 52

C-peptide is released by the pancreas into the bloodstream in equal amounts to insulin and reflects how much insulin pancreatic beta cells are making. The mixed meal tolerance test (MMTT) was performed in the morning, and blood samples for C-peptide were collected at baseline (pre-meal) and various minutes post-meal at each visit and analyzed by a central laboratory. C-peptide area under the curve (AUC) was calculated using the trapezoidal rule over the 2-hour time period. Larger numbers are better in these AUC results: more insulin being produced reflects less severe disease. The mean 2-hour C-peptide AUC, measured in nmol/L, is computed by dividing the total AUC by the length of the MMTT (e.g. 120 minutes).

At Weeks 12, 24, 36, 52
Insulin Use (U/kg/Day)
Zeitfenster: At Weeks 6, 12, 24, 36 and 52.

Measured as U/kg body weight/day; participants recorded the type and amount of insulin they have used during the 5-day period immediately preceding the beginning of treatment, middle of treatment, end of treatment, and at all follow-up visits

At Weeks 6, 12, 24, 36 and 52.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Studienstuhl: Stephen Gitelman, M.D., University of California San Francisco, School of Medicine: Diabetes Center

Publikationen und hilfreiche Links

Die Bereitstellung dieser Publikationen erfolgt freiwillig durch die für die Eingabe von Informationen über die Studie verantwortliche Person. Diese können sich auf alles beziehen, was mit dem Studium zu tun hat.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

18. Mai 2023

Primärer Abschluss (Tatsächlich)

14. Mai 2025

Studienabschluss (Tatsächlich)

20. Oktober 2025

Studienanmeldedaten

Zuerst eingereicht

19. September 2022

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

6. Oktober 2022

Zuerst gepostet (Tatsächlich)

10. Oktober 2022

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

13. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

21. Oktober 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • DAIT ITN095AI

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

JA

Beschreibung des IPD-Plans

Immunology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.

IPD-Sharing-Zeitrahmen

On average, within 24 months after database lock for the trial.

IPD-Sharing-Zugriffskriterien

Open access.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .